Associations between objective response to first-line post-olaparib platinum-based chemotherapy and (i) olaparib response, (ii) pre-olaparib platinum sensitivity (measured by TFI), and (iii) interval between last pre-olaparib and first post-olaparib platinum-based chemotherapies (PTP interval)
| Post-olaparib platinum chemotherapy response by RECIST and/or GCIG criteria | |||||
|---|---|---|---|---|---|
| SD vs. PD | PR/CR vs. PD | ||||
| P | OR (95% CI) | P | OR (95% CI) | ||
| Olaparib response by RECIST and/or GCIG | SD vs. PD | 0.105 | 14 (0.58–338.78) | 0.184 | 7.0 (0.40–123.35) |
| PR/CR vs. PD | 0.341 | 3.6 (0.26–50.33) | 0.275 | 3.4 (0.38—30.66) | |
| TFI after last pre-PARPi platinum (months) | 0.874 | 1.008 (0.915–1.110) | 0.921 | 1.005 (0.916–1.102) | |
| PTP interval (months) | 0.061 | 1.117 (0.995–1.254) | 0.045 | 1.124 (1.003–1.264) | |